Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611868 · ClinicalTrials.gov registry record · Phase 1
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
A Phase 1 study of Melanoma and Cutaneous Melanoma, sponsored by Ascentage Pharma Group.
- Active
- Registry status
- Phase 1
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT03611868 is a Phase 1 study of Melanoma and Cutaneous Melanoma that is active but no longer recruiting, run by Ascentage Pharma Group. The registered enrollment target is 230 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03611868, a Phase 1 study of Melanoma and Cutaneous Melanoma, is active but no longer recruiting, sponsored by Ascentage Pharma Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Conditions Studied
Interventions
- DRUG Phase 1b: APG-115+pembrolizumab
Study Locations (20)
California
- UCLA Hematology & Oncology Clinic - Los Angeles
- Sarcoma Oncology Research Center - Santa Monica
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic - Cleveland
Pennsylvania
- Penn State Hershey Medical Center Cancer Institute - Hershey
- Thomas Jefferson University Hospital - Philadelphia
Texas
- University of Texas MD Anderson Cancer Center - Houston
- Next Oncology - San Antonio
Queensland
- Metro South Hospital and Health Services via Princess Alexandra Hospital - Brisbane
- Queensland Children's Hospital - South Brisbane
Arizona
- University of Arizona Cancer Center - Tucson
Arkansas
- Highlands Oncology - Rogers
District of Columbia
- Children's National Research Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2018-08-29 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611868
The ClinicalTrials.gov registry entry for NCT03611868 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (67% lower). The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Phase 1b: APG-115+pembrolizumab is the first listed.
NCT03611868 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03611868 about?
NCT03611868 is a clinical study titled "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors". This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hyp...
What is the current status of trial NCT03611868?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2018-08-29. Estimated completion is 2025-12-30.
What conditions does trial NCT03611868 study?
This clinical trial studies the following conditions: Melanoma, Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST).
What interventions are being tested in trial NCT03611868?
The interventions under investigation include: Phase 1b: APG-115+pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03611868?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03611868 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.